Get the app
USHealthcare

Savara Inc (SVRA)

US · Healthcare · Biotechnology

$5.42+5.65%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-40.2M
EPS
$-0.16
EPS estimate
$-0.14

EPS came in at -0.16 against a street estimate of -0.14 — a miss of 14.3%.

Key statistics

Market cap
$1.09B
Forward P/E
0.4
P/B
7.59
Book value
$0.56
EPS (TTM)
$-0.58
52-week high
$7.00
52-week low
$3.34
50-day MA
$5.60
200-day MA
$5.60
Beta
0.25

Analyst view

Analysts rate Savara Inc a buy (6 buy, 2 hold, 0 sell out of 8) with an average price target of $10.94.

Shareholding

Insiders
2.59%
Institutions
106.66%

Largest institutional holders

FundStake
NEA Management Company, LLC11.91%
Bain Capital Life Sciences Investors, LLC8.57%
VR Adviser, LLC6.69%
Deerfield Management Co6.60%
TCG Crossover Management, LLC6.02%
BlackRock Inc5.50%
Frazier Life Sciences Management, L.P.4.73%
Polar Capital Holdings PLC4.64%

Recent filings & reports

DocumentDate
Quarterly report · Q2 2026
SAVARA INC. – 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash position: $41.8 million cash + $131.2 million short-term investments = $173 million tot
2026-08-11
Board / officer change · Q2 2026
SAVARA INC. (SVRA) - 8-K SUMMARY HEADLINE NUMBERS • Stockholders approved increase in authorized common stock shares from 300,000,000 to 600,000,000
2026-06-08
Quarterly report · Q1 2026
SAVARA INC. - 10-Q SUMMARY FOR Q1 2026 HEADLINE NUMBERS • Cash and investments: $38.8 million cash + $164.0 million short-term investments = $202.8
2026-05-12
Proxy statement · Q2 2026
SAVARA INC. PROXY STATEMENT SUMMARY CEO COMPENSATION • Matthew Pauls (CEO and Chair): Total 2025 compensation was $3,455,788 • This consists of: $500
2026-04-24
Annual report FY2025
SAVARA INC. – 10-K SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Company: Savara Inc. (ticker: SVRA, Nasdaq) • Market cap (as of June 30, 202
2026-03-13
Material agreement · Q1 2026
SAVARA INC. (SVRA) - 8-K FILING SUMMARY March 10, 2026 --- BUSINESS & SEGMENT HIGHLIGHTS • Savara Inc. is a biopharmaceutical company (ticker: SVRA
2026-03-13
Material agreement · Q1 2026
SAVARA INC. (SVRA) - 8-K SUMMARY HEADLINE NUMBERS • Total borrowing capacity under amended Loan and Security Agreement: $105 million in term loans •
2026-01-27
Reg FD disclosure · Q1 2026
SAVARA INC. (SVRA) - 8-K SUMMARY HEADLINE NUMBERS • Filing Date: January 9, 2026 • Company: Savara Inc., a Delaware corporation • Stock Symbol: SVRA
2026-01-09

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Savara Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Data updated 2026-09-18.